To the full analysis
Swedish Orphan Biovitrum stock: growth
SOBI.STSwedish Orphan Biovitrum reported $2.83B in revenue for fiscal 2025, up 8.5% on the prior year, up 13.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
18.1%
per year from 2006 to 2025, per share 10.8%
Earnings (Annual rate)
9%
per year from 2006 to 2025, per share 2.3%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 13.1% | 24.2% | 18.1% |
| Revenue per share | 10.6% | 21.1% | 10.8% |
| Earnings | −31.8% | 21.5% | 9.0% |
| Earnings per share | −33.3% | 19.2% | 2.3% |
| Free cash flow | 44.3% | 37.2% | no data |
| Free cash flow per share | 41.2% | 33.8% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $120.44M | $9.29M | −$24.31M |
| 2007 | $125.98M | $7.92M | −$16.57M |
| 2008 | $114.37M | −$33.63M | −$71.37M |
| 2009 | $130.05M | $3.25M | −$10.01M |
| 2010 | $191.19M | −$10.47M | −$33.88M |
| 2011 | $191.6M | $1.8M | $8.79M |
| 2012 | $192.84M | −$10.12M | $33.81M |
| 2013 | $218.26M | −$9.32M | −$22.54M |
| 2014 | $261.41M | −$26.86M | $5.08M |
| 2015 | $323.66M | $6.86M | $36.21M |
| 2016 | $521.85M | $81.13M | $17.89M |
| 2017 | $652.85M | $115.17M | $119.67M |
| 2018 | $916.37M | $242.44M | $151.65M |
| 2019 | $1.43B | $331.3M | −$612.86M |
| 2020 | $1.53B | $325.38M | $136.57M |
| 2021 | $1.56B | $268.63M | $511.38M |
| 2022 | $1.88B | $264.52M | $310.74M |
| 2023 | $2.22B | $241.55M | −$47.43M |
| 2024 | $2.61B | $389.55M | $439.49M |
| 2025 | $2.83B | $47.93M | $854.71M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.